Skip to content

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

News

Select Year
Clinical Trials
Search …

January 23, 2007

Oncolytics Biotech Inc. Announces Appointment of Vice President, Intellectual Property

January 16, 2007

Oncolytics Biotech Inc. Announces Issuance of 18th U.S. Patent

January 10, 2007

Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Data at Society of Academic & Research Surgery Conference

January 3, 2007

Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Docetaxel

January 3, 2007

Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Gemcitabine

Page 71 of 71

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

Our Mission
Leadership
Board of Directors
Careers
Contact

Science

Our Science
Pipeline
Resources

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent

Copyright © 2026 Oncolytics Biotech Inc.